Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Contraceptive Compliance Studies May Be Key To Assessing Risk Of Ortho Evra Patch

Executive Summary

Some patients in an FDA-funded study had less risk for blood clots than others and finding the reason is a subject for future studies, several members of an advisory panel told FDA Dec. 9. The Reproductive Health Drugs and Drug Safety and Risk Management Committees concluded in a 19-5 vote that the drug’s benefits outweigh its risks.

You may also be interested in...



Oral Contraceptives Petition Seeking Ban On Third-Generation Products Denied By FDA

Public Citizen losses again as the agency says current product labeling for desogestrel-containing oral contraceptives adequately describes the risk of venous thromboembolism; FDA notes the difficulty in comparing the magnitude of risks between combination OCs.

FDA’s Risk Disclosure Challenges Highlighted At Contraceptive Advisory Cmte.

Uncertainty remained the dominant opinion about the risk for blood clots with the four Bayer contraceptives at the conclusion of a Dec. 8 joint meeting of the Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committees. One thing panelists were sure of was that they didn’t want a summary conclusion about the risks in labeling. But they didn’t want a lengthy discussion of data, either.

Transdermal Delivery Trumps Advisory Panel Concerns About Blood Clots With J&J’s Ortho Evra

With an eye toward keeping the contraceptive patch as an alternative to birth control pills, the Reproductive Health Drugs and Drug Safety and Risk Management Committees voted 19-5 on Dec. 9 that the benefits of the contraceptive patch outweigh its risks.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel